trial summary · NCT07703436
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial record from the TrialBase DB dataset, status RECRUITING, condition Grade 2 IDH1-mutant Glioma, sponsored by Nuvation Bio Inc.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
Source record: https://clinicaltrials.gov/study/NCT07703436
Facts
| registry id | NCT07703436 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Grade 2 IDH1-mutant Glioma |
| sponsor | Nuvation Bio Inc. |
| sponsor class | INDUSTRY |
| enrollment | 40 |
| start date | 2027-03 |
| primary completion | 2030-09 |
| completion | 2032-03 |
| results posted | not reported |
Conditions
- Grade 2 IDH1-mutant Glioma
- Grade 3 IDH1-mutant Glioma
- Glioma
- IDH1-mutant Glioma
- Oligodendroglioma
- Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted
- Astrocytoma IDH Mutant Grade 3
- Astrocytoma IDH Mutant Grade 2
Interventions
- Safusidenib
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.